Equities Analysts Issue Forecasts for ADCT FY2025 Earnings

ADC Therapeutics SA (NYSE:ADCT) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for ADC Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($1.66) per share for the year. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share.

ADC Therapeutics (NYSE:ADCT) last announced its earnings results on Thursday, November 7th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.06). The firm had revenue of $18.46 million for the quarter, compared to analyst estimates of $18.76 million. During the same quarter in the prior year, the company posted ($0.58) earnings per share.

Several other equities analysts have also issued reports on ADCT. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of ADC Therapeutics in a report on Monday, January 6th. Stephens assumed coverage on ADC Therapeutics in a research report on Friday, November 8th. They set an “overweight” rating and a $6.00 target price on the stock. Finally, Guggenheim reissued a “buy” rating and issued a $10.00 price target on shares of ADC Therapeutics in a report on Thursday, December 12th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, ADC Therapeutics currently has an average rating of “Buy” and a consensus target price of $8.00.

ADC Therapeutics Trading Down 3.6 %

Shares of ADCT stock opened at $1.77 on Wednesday. The stock has a market capitalization of $170.66 million, a price-to-earnings ratio of -0.74 and a beta of 1.55. ADC Therapeutics has a twelve month low of $1.68 and a twelve month high of $6.04. The stock has a fifty day simple moving average of $2.14 and a two-hundred day simple moving average of $2.76.

Institutional Trading of ADC Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Susquehanna Fundamental Investments LLC purchased a new stake in shares of ADC Therapeutics during the 2nd quarter valued at approximately $33,000. Intech Investment Management LLC purchased a new position in shares of ADC Therapeutics during the 3rd quarter worth $41,000. Readystate Asset Management LP acquired a new stake in shares of ADC Therapeutics during the 3rd quarter worth about $54,000. SG Americas Securities LLC purchased a new stake in ADC Therapeutics in the 3rd quarter valued at about $84,000. Finally, The Manufacturers Life Insurance Company acquired a new position in ADC Therapeutics in the second quarter valued at about $85,000. 41.10% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other ADC Therapeutics news, major shareholder Redmile Group, Llc bought 100,000 shares of the stock in a transaction on Wednesday, December 11th. The shares were bought at an average price of $3.04 per share, with a total value of $304,000.00. Following the purchase, the insider now directly owns 13,145,712 shares in the company, valued at $39,962,964.48. This trade represents a 0.77 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.10% of the stock is currently owned by company insiders.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.